By Paul Raeburn
FairWarning
Off-label promotion has long been considered a serious white-collar crime. The FDA has fined drug companies billions of dollars for off-label violations. The aim: to prevent them from overstating the benefits and understating the risks of their products, a practice known as misbranding – and one that sometimes leads to patients getting drugs that prove harmful or even deadly.
We are a 501(c)(3) organization. All donations are tax deductible.
Join Our Email List
Florida Bulldog delivers fact-based watchdog reporting as a public service that’s essential to a free and democratic society. We are nonprofit, independent, nonpartisan, experienced. No fake news here.
